Jonathan Badrock

Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score

Marco Carbone, Alessandra Nardi, Steve Flack et al. · ˜The œLancet. Gastroenterology & hepatology · 2018 · 163 citations · Full text

Medicine, Internal Medicine, Hepatology +9

The Serum Proteome and Ursodeoxycholic Acid Response in Primary Biliary Cholangitis

Ben Barron‐Millar, Laura Ogle, George Mells et al. · Hepatology · 2021 · 57 citations · Full text

Life Sciences, Biochemistry, Clinical Sciences +17

Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial

Andrew R. Clamp, Elizabeth C James, Iain A. McNeish et al. · The Lancet Oncology · 2022 · 45 citations · Full text

Medicine, Gynecology, Oncology +14

Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19

Eleftherios Mylonakis, Barnaby Edward Young, David M. Vock et al. · Annals of Internal Medicine · 2022 · 31 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +13

Bacterial and metabolic phenotypes associated with inadequate response to ursodeoxycholic acid treatment in primary biliary cholangitis

Laura Martínez-Gili, Alexandros Pechlivanis, Julie A. K. McDonald et al. · Gut Microbes · 2023 · 28 citations · Full text

Medicine, Internal Medicine, Microbiology +17